To assess the early visual performance and subjective experience of patients implanted with a new lower near vision addition segmented multifocal intraocular lens

Session Details

Session Title: Pseudophakic IOLs: Multifocal II

Session Date/Time: Sunday 08/10/2017 | 10:30-12:30

Paper Time: 12:02

Venue: Room 2.1

First Author: : S.Shah UK

Co Author(s): :    E. Berrow   R. Gil-Cazorla   S. Naroo   J. Wolffsohn           

Abstract Details

Purpose:

To assess the early visual performance and subjective experience of patients implanted with a new lower near vision addition for a bi-aspheric, segmented, multifocal intraocular lens (MIOL): the SBL-2 (Lenstec Inc, St Petersburg, FL, USA).

Setting:

Private ophthalmology clinic, Solihull, United Kingdom.

Methods:

20 patients (age 63.3 ± 13.2 years) were implanted with the SBL-2 (a low add segmental multifocal lens). Three months after implantation, assessment was made of: manifest refraction; uncorrected (UCDVA), best corrected distance visual acuity; photopic defocus curves over a range of +1.5 to -5.0 D in 0.5 Dioptres in randomised manner; contrast sensitivity using the Pelli-Robson chart; halometry, as an objective measure of glare, using randomised letters moving away from a glare source in randomised 45 degree meridian increments to quantify the obscuring effect of the halo; patient’s satisfaction with UCDVA, using the Near AcuityVisual Questionnaire.

Results:

Mean residual manifest refraction was +0.10 ± 0.52D. Mean UCDVA was +0.09 ± 0.15 logMAR. Mean monocular UCNVA was 0.24 ±0.16 logMAR, improving to and BCNVA was 0.19 ±0.15 logMAR with distance correction. Eighty four percent of eyes (84%) could read 0.3 LogMAR or better without any reading correction. Mean contrast sensitivity was 1.62 ±0.13 log units. Halometry showed a glare profile of less than 1 degree of debilitating light scatter. Mean NAVQ Rasch score for satisfaction for near vision was 22.1 ± 19.0 logits.

Conclusions:

The SBL-2 MIOL provides a good visual outcome at distance and near with minimal dysphotopsia near vision.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a competing company, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a competing company, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives consulting fees, retainer, or contract payments from a competing company